NCT06786520View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

March 9, 2027

Study Completion Date

November 8, 2027

Conditions
HIV Infections
Interventions
DRUG

CAB LA

CAB LA injection will be administered

DRUG

CAB ULA

CAB ULA injection will be administered

Trial Locations (3)

33134

GSK Investigational Site, Coral Gables

36608

GSK Investigational Site, Mobile

60532

GSK Investigational Site, Oak Brook

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY

NCT06786520 - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | Biotech Hunter | Biotech Hunter